A2LQV6 KKR & Co Inc

KKR Partners with Duke Rohlen to Create Medical Device Platform

KKR, a leading global investment firm, and Duke Rohlen, a 20-year medical device veteran, today announced the formation of Zeus Health (“Zeus”), a $100 million platform focused on investing in and operating a portfolio of emerging medical device companies.

Zeus marks the continuation of a long-standing relationship between KKR and Mr. Rohlen. Throughout his career, Mr. Rohlen has successfully led, grown and exited multiple medical device companies, including alongside KKR. In 2016, KKR invested in Spirox, an ENT-focused medical device company led by Mr. Rohlen as CEO. Spirox was sold to Entellus Medical in 2017, and the combined business was sold to Stryker shortly thereafter in 2018. In 2017, KKR and Mr. Rohlen formed Ajax Health, a medical device platform company whose primary asset EpiX Therapeutics was sold to Medtronic in 2019.

“We are excited to have the opportunity to work with Duke and his team again, now for the third time following our previous success with Ajax Health and Spirox. Duke is a proven leader in the medical device field, as are his team of industry and operational experts. We look forward to working together to identify and scale much-needed next-generation medical technologies,” said Ali Satvat, Global Head of KKR Health Care Strategic Growth and Co-Head of Health Care within KKR’s North America Private Equity platform.

“With the formation of Zeus Health, I am thrilled to further deepen my relationship with KKR, whose unmatched reputation, scale and depth of health care expertise will continue to open new doors for us as we look to bring innovative medical devices to patients in need,” said Mr. Rohlen.

For KKR, the investment in Zeus Health is being funded through the firm’s , which is focused on investing in high-growth health care-related companies for which KKR can be a unique partner in helping reach scale. KKR has established a strong track record of supporting health care companies, having invested approximately $14 billion across the sector since 2004.

About KKR

KKR is a leading global investment firm that manages multiple alternative asset classes, including private equity, credit and real assets, with strategic partners that manage hedge funds. KKR aims to generate attractive investment returns for its fund investors by following a patient and disciplined investment approach, employing world-class people, and driving growth and value creation with KKR portfolio companies. KKR invests its own capital alongside the capital it manages for fund investors and provides financing solutions and investment opportunities through its capital markets business. References to KKR’s investments may include the activities of its sponsored funds. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at and on Twitter @KKR_Co.

EN
17/11/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on KKR & Co Inc

KKR & Co Inc: 1 director

A director at KKR & Co Inc sold 809,906 shares at 144.250USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

 PRESS RELEASE

KKR Appoints Timothy R. Barakett to Board

NEW YORK--(BUSINESS WIRE)-- KKR & Co. Inc. (NYSE: KKR) today announced that Timothy R. Barakett has been appointed to the Board of Directors effective March 13, 2025. His appointment will bring the number of independent directors to ten out of a total of fourteen Board seats. This press release features multimedia. View the full release here: Timothy R. Barakett (Photo: Business Wire) Mr. Barakett is the Founder and Chief Executive Officer of TRB Advisors, a private investment firm and family office. Prior to founding TRB Advisors in 2010, Mr. Barakett was the Founder and Chief Executive Offic...

 PRESS RELEASE

Darwinbox Raises $140 Million Investment Co-led by Partners Group and ...

HYDERABAD, India--(BUSINESS WIRE)-- , a leading global human resource (“HR”) technology platform, today announced the signing of definitive agreements under which Partners Group, one of the largest firms in the global private markets industry (acting on behalf of its clients), and funds managed by KKR, a leading global investment firm, will co-lead an investment of $140 million in the company, with additional participation from Gravity Holdings. The addition of Partners Group and KKR to an already-solid cap-table underscores Darwinbox’s strong momentum over the recent years. The investment pos...

 PRESS RELEASE

KKR to Sell Seiyu to Trial Holdings

TOKYO--(BUSINESS WIRE)-- KKR, a leading global investment firm, and Seiyu, a nationwide supermarket chain in Japan, today announced the signing of definitive agreements to sell Seiyu (the “Company”) to Trial Holdings, Inc. (TSE stock code 141A; “Trial”), a distribution and retail business operator in Japan that operates a network of stores offering “everyday essentials” in Kyushu. This transaction represents a significant outcome for KKR and follows transformational work that positions Seiyu strongly for continued success. This press release features multimedia. View the full release here: KK...

 PRESS RELEASE

KKR Upsizes and Prices Offering of Mandatory Convertible Preferred Sto...

NEW YORK--(BUSINESS WIRE)-- KKR & Co. Inc. (“KKR”) (NYSE: KKR) today announced that it has priced its previously announced offering of $2.25 billion (45,000,000 shares) of its 6.25% Series D Mandatory Convertible Preferred Stock (the “mandatory convertible preferred stock”) at a price to the public and liquidation preference of $50.00 per share. The offering was upsized from the previously announced size of $1.50 billion (30,000,000 shares). The underwriters have a 30-day option to purchase up to an additional $337.50 million (6,750,000 shares) of mandatory convertible preferred stock, solely ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch